The term slow launch is subtle and Davis probably didn't realize the impact it would have. Also when Davis was thanking everyone he never said Thank you to the shareholders.
You say he is " Senior research analyst ... neurology, CNS..." Sounds like he knows his stuff. And I will totally ignore the spelling error since I can't spell either, but I somehow managed to get though college majoring in Biochemistry(UCR) and Medical School (AECOM).
I think his background is pretty good, Chemist, Research Harvard Med School / Brigham, not sure why you would call him a joke. You think getting a degree in Chemistry is that easy? Einstein was like a patent clerk. I didn't read his downgrade...but not surprised...the Post Approval conference was...lets say, short of knocking it out of the park. If they would have given specific date of LAUNCH, specific PRICING, specific date of EU NDA specific PARTNERSHIP info, etc then maybe the analyst wouldn't have downgraded...I don't know.
Thanks....I totally understand. As far as off label, it will take a while, but sooner of later the payers with figure out paying for Nuplazid is cheaper than putting patients in the hospital or giving them drugs with SAE.
Yes, I don't recall their name but they are in Europe, ?Swiss. It has been all set up, the QA is complete and inspected. There is no issue with this manufacturer.
Davis..."" we plan to set and announce the price of NUPLAZID between approval and launch, so we've not yet set the price, we plan to do that shortly. ""
Davis...."So, Cory, as we have previously stated, we expect to submit in Europe in the first half of this year. "
Davis..." .... we haven't yet made a determination whether we will launch the drug ourselves outside of the U.S. or partner. I think now is not the time to partner... as we get closer to approvals outside of the United States, we will make a determination whether the best result for us is to partner in one or more partnerships outside of the U.S. or launch the drug ourselves. We are preparing for both."
Davis..." ... for NUPLAZID we have composition - various layers of composition of matter patents. The important point is that in the United States, our composition of matter patents take us into 2028 pre-Hatch Waxman. Given that we are launching the drug this year, we will likely hit the 14-year limit for Hatch Waxman before hitting the full potential Hatch Waxman extension. So that should take us into 2030 in the United States.
Davis...about 1 million Parkinson's patients in the U.S., about 40% of them or 400,000 suffer from Parkinson's disease psychosis. Of those about half of them have what physicians typically refer to as disruptive symptoms. we know to be approximately or right at 150,000 patients being treated today with off label antipsychotics.
Moore...For those who are taking other medications off label such as Seroquel, what we have been told is, based on a blinded product profile, that there are very good reasons to switch their patients from Seroquel to NUPLAZID.
Can someone explain this part of Terry Moore's presentation, ....." NUPLAZID is an oral product and covered as a pharmacy benefit. So it does not need a J Code and does not require a physician to take on any financial risk. "............. specifically, what is a J code and why would a physician have to take on financial risk ?
Man all I could think about was how much Serge sounds like the late actor Raul Julia, perhaps you remember him from the movie , " Presumed Innocent ", Great actor.
Recent CandleStick Analysis
Apr-28-2016 Bearish Harami
This is not my analysis guys just what I note from stockta...you are welcome to ignore it.
I am opening a candy store...I have a very unique candy and I think a lot of people will love it...it will be local at first but then it will grow but grow where? Also I need to get some helpers ? Or do I just want to work the store myself...gotta think about that....I am not sure how much to sell my candy for too ... Geez feeling the heat and haven't even sold one candy yet.
OK so far no big pop...not only that but its way down,Red. I would cry manipulation but the TA has been bearish for a while. I just figured the Approval would carry us over the Resistance easily...well not so. We are still holding hands with the IBB. Time for a strategy adjustment. Personally, I have not sold 1 share. I don't think we are too far from a reversal, but I hate to say it, it could come after more of a shake out. Big Red candle today so far spells more selling in the future- a so called sell the news scenario. We didn't get the Big news in the conference...Price of Nuplazid?..Partnership?...Date for EU NDA?....and the launch info seemed confusing( somebody clarify that for me please ). So sounds like we are gonna have to give it a little TIME...things have to fall into place gradually, we are a small biotech and word really is not out yet, new Analyst Price Targets will help, but they don't have the pricing either. But what we do have ? an Approved drug that can only be ignored for so long. We need management to get off the pot and give us the answers we need to move this stock forward. Technically - way Over Sold.
To me TA has more to do with patterns, lines, bars, candle sticks, charting, indicator which are many. Do you see that in my post NO....merely R&S levels that I copied and pasted - that is NOT TA. So when the airline stewardess tells you your seat cushion can be used as a flotation device .....you believed her?